Biotech startup PopVax begins human trials of fridge-stable covid vaccine
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Hyderabad-based biotech startup PopVax has started human trials of its fridge-stable covid vaccine, PVX-001.
- ✓The vaccine stays stable at 2-8°C for nine months.
- ✓Founder Soham Sankaran said, "We really wanted this to be compatible with whatever existing distribution chains are there." The firm plans to make the design open-source.
Story at a Glance
- Category
- MARKET
- Reported By
- mint
- Reading Speed
- 4 Minute(s)
- Market Focus
- India Economy
Summary
PopVax's PVX-001 is designed to remain stable at 2-8°C for at least nine months and protect against a broad range of covid-19 variants
Hyderabad-based biotech startup PopVax has begun human trials of an RNA vaccine candidate for covid-19 designed to remain stable at refrigerator temperatures for at least nine months, potentially easing distribution in countries with limited cold-chain infrastructure.
The company has dosed the first participants in a phase 1 clinical trial of PVX-001, a vaccine candidate designed to protect against a broad range of SARS-CoV-2 variants. PopVax plans to make the vaccine design open-source after the trial, allowing other researchers and manufacturers to build on it for future coronavirus outbreaks.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
mint
Read the full, original unfiltered story directly on the publisher's portal.